When performing subgroup analysis, it was noted that the high expression of PAK6 was negatively associated with the survival rate of the patients who were treated with surgery only (P = 0.095, Fig. 1b), but strongly correlated with poor prognosis of patients who were treated with surgery followed by chemotherapy (P = 0.002, Fig. 1c), indicating PAK6 might modulate drug sensitivity in gastric cancer. The gene discussed is PAK6; the disease is gastric cancer.